Product Program year 2020 Source: CMS Open Payments

Feraheme

Drug Parenteral Iron Replacement

NDC 59338-775-01

Open in the dashboard

General payments

$1,185,893

3,365 payments

Research payments

$1,184,441

82 payments

Through program year 2020, $1,185,893 in general payments and $1,184,441 in research payments were reported against Feraheme (Parenteral Iron Replacement).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

4 rows
Year Kind Amount Payments
2020 General $664,510 727
2020 Research $120,693 42
2019 General $521,383 2,638
2019 Research $1,063,748 40

Breakdown

Who paid General payments · program years 2019–2020
  1. AMAG Pharmaceuticals, Inc. $1,185,893 3,365 payments
Top recipients General payments · program year 2020
  1. Ohsu Hospital And Clinics Teaching hospital · OR $607,164 91% · 3 payments
  2. David Soffa Diagnostic Radiology · San Francisco, CA $15,300 2% · 3 payments
  3. Anita Nelson Obstetrics & Gynecology · Torrance, CA $12,428 2% · 4 payments
  4. Draupadi Talreja Hematology & Oncology · Northridge, CA $6,364 <1% · 8 payments
  5. Suresh Ratnam Medical Oncology · McAllen, TX $4,578 <1% · 7 payments

The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2020.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2020
  1. Hematology & Oncology Internal Medicine $16,342 29% · 264 practitioners
  2. Diagnostic Radiology Radiology $15,366 28% · 5 practitioners
  3. Obstetrics & Gynecology $12,604 23% · 9 practitioners
  4. Medical Oncology Internal Medicine $6,207 11% · 79 practitioners
  5. Nephrology Internal Medicine $1,417 3% · 78 practitioners

The top 5 of 34 specialties; each share is of general payments naming this product to practitioners with a specialty in 2020. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2020
  1. Oregon $607,164 91% · 1 recipient
  2. California $36,993 6% · 94 recipients
  3. Texas $5,250 <1% · 38 recipients
  4. Florida $4,763 <1% · 60 recipients
  5. New Jersey $1,160 <1% · 19 recipients

The top 5 of 40 states; each share is of general payments naming this product in 2020 where a state was reported.

The top 25 states, free in the app

Given in the clinic

Part B · billing code
Medicare Part B billing codes matched to FERAHEME
Billing code Providers Services Paid by Medicare
Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) Q0138 977 26,842,035 $7,312,080

Drugs given by a clinician are billed to Medicare Part B, not Part D. The product is tied to a billing code through the NDC on CMS's crosswalk, which was published for a later quarter than the payments, so a code that changed in between can be missed. Providers with fewer than 11 patients for the code are not published. Medicare's payment here is what it paid for the services, to the billing practice.

3,365 general · 82 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2020

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record